GlobeImmune Announces Late-Breaker Presentation of Interim Efficacy and Safety Data for GI-5005 at AASLD 2008 Meeting
September 24, 2008 13:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - September 24, 2008) - GlobeImmune, Inc. today announced that a
late breaking abstract related to GI-5005, its investigational hepatitis C
virus (HCV) product candidate,...
GlobeImmune Signs CRADA With the National Institutes of Health to Develop Cancer Therapeutics
July 09, 2008 07:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - July 9, 2008) - GlobeImmune, Inc. announced today the
signing of a Cooperative Research and Development Agreement (CRADA) with
the National Cancer Institute (NCI) at the...
FierceBiotech Names GlobeImmune as One of the "Fierce 15" Biotech Companies of 2008
June 24, 2008 13:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - June 24, 2008) - FierceBiotech and GlobeImmune, Inc.
announced today that GlobeImmune has been named to the annual FierceBiotech
"Fierce 15" list, designating it as one...
GlobeImmune Announces Completion of Planned Enrollment for GI-5005-02 Phase 2 Trial in Chronic Hepatitis C Patients
May 20, 2008 16:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - May 20, 2008) - GlobeImmune, Inc. announced today completion
of the planned enrollment of 120 subjects in a Phase 2 clinical trial to
evaluate the GI-5005 Tarmogen®...
GlobeImmune Announces Appointment of J. William Freytag, Ph.D to Its Board of Directors
March 25, 2008 07:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - March 25, 2008) - GlobeImmune, Inc. announced today the
addition of J. William Freytag, Ph.D. to its Board of Directors.
"Dr. Freytag brings over 25 years of research,...
GlobeImmune Announces Initiation of a Phase 2a Clinical Trial of GI-4000 in Patients With Non-Small Cell Lung Cancer at Memorial Sloan Kettering
March 19, 2008 07:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - March 19, 2008) - GlobeImmune, Inc. announced today the
initiation of a Phase 2a clinical trial at Memorial Sloan Kettering Cancer
Center (MSKCC) to evaluate...
GlobeImmune to Present at the JPMorgan Healthcare Conference
January 03, 2008 07:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - January 3, 2008) - GlobeImmune, Inc. announced today that
President and Chief Executive Officer, Timothy C. Rodell, M.D., will
present at the JPMorgan Healthcare...
GlobeImmune Announces Initiation of Phase 2 Clinical Trial of GI-5005 in Patients With Chronic Hepatitis C
December 19, 2007 07:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - December 19, 2007) - GlobeImmune, Inc. announced today the
initiation of the Company's Phase 2 clinical trial to evaluate GI-5005
Tarmogen® for the treatment of...
GlobeImmune Announces Presentation of Results From a Randomized Phase 1b Study of the GI-5005 Tarmogen in Patients With Chronic Hepatitis C Infection
November 06, 2007 17:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - November 6, 2007) - GlobeImmune, Inc. today announced results
from the additional higher dose cohorts from the Company's randomized,
placebo-controlled Phase 1b clinical...
GlobeImmune Announces Presentation of Additional Phase 1b Hepatitis C Results at American Association for the Study of Liver Diseases 2007 Annual Meeting
November 01, 2007 08:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - November 1, 2007) - GlobeImmune, Inc. today announced that
additional high dose results from the Company's randomized,
placebo-controlled Phase 1b clinical trial...